Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
Condition(s) studied
Investigational drug(s) / intervention(s)
Fluoxetine: Commonly used oral antidepressant.
Sertraline: Commonly used oral antidepressant.
Vortioxetine: Commonly used oral antidepressant.
Duloxetine: Commonly used oral antidepressant.
Aripiprazole: Commonly used oral augmentation therapy for antidepressants
Lithium Carbonate: Commonly used oral augmentation therapy for antidepressants.
Olanzapine: Commonly used oral augmentation therapy for antidepressants.
GCBT: Commonly used intervention therapy of psychotherapy.
Study summary
This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.
Eligibility
Primary outcome measure(s)
- Change in CDRS-R (Children's Depression Rating Scale) scores from baseline — Baseline of treatment period, 2 weeks, 1 month, 2 months, 3 months,4months; The follow-up period was 1 month, 3 months, 6 months and 12 months
Clinical response (≥ 50% reduction in CDRS-R scores from baseline)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | Province | Recruiting |
On this site
📄 Zoloft (sertraline) drug profile → 📄 Trintellix (vortioxetine) drug profile → 📄 Cymbalta (duloxetine) drug profile → 📄 Abilify (aripiprazole) drug profile →More First Affiliated Hospital of Chongqing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05814640 on ClinicalTrials.gov ↗ ← All trials in China